PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency

NCT06302439

Status	RECRUITING
Sponsor	Inozyme Pharma
Enrollment	1,000 participants

Key Eligibility Criteria

Inclusion (16)

- Must provide written or electronic consent after the nature of the registry has been explained, and prior to any research-related procedures, per International Council for Harmonisation (ICH) Good Clinical Practice (GCP)
- Agree to provide access to relevant medical records
- One of the following genetic or clinical criteria
- A confirmed prenatal or postnatal molecular genetic diagnosis of ENPP1 Deficiency with biallelic mutations (ie, homozygous or compound heterozygous) performed by a College of American Pathologists/Clinical Laboratory Improvement Amendments (CAP/CLIA) certified laboratory or regional equivalent
- OR

... and 11 more (see full listing online)

Exclusion (3)

- Participant or their legally designated representative does not have the cognitive capacity to provide informed consent
- Patients who are currently participating in an INZ-701 interventional clinical study, with the exception of expanded access programs and long-term safety follow-up studies
- Participants in interventional studies may be approached for inclusion in the registry once their involvement in the treatment period of the clinical study has been completed

Locations (14 total)

Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
Boston Children's Hospital, Boston, Massachusetts, United States
Mayo Clinic, Rochester, Minnesota, United States
... and 11 more locations